SCHOOL platform: Biophysical principles

SCHOOL platform for receptor signaling

SCHOOL concept: Learning from viruses

SCHOOL approach to sepsis, lung cancer, breast and pancreatic cancer, autoimmune diseases and others


Multichain Immune Recognition Receptor Signaling From Spatiotemporal Organizaiton to Human Disease


  • SignaBlok has been highlighted by Mass High Tech as a top company to watch
    Read more
  • SignaBlok targets $2.5M funding to treat lung, breast cancer
    Read more
  • SignaBlok aims to condense virus evolution, discover new drug solutions
    Read more
  • UMass research focuses on anti-clotting platform
    Read more

Contact Us

SignaBlok, Inc.
P.O. Box 4064
Shrewsbury, MA 01545


Please use the form below to send us any questions or comments you may have.















Fact Sheet

Press Releases

  • SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis
    Read more
  • SignaBlok Wins NIH Grant to Advance New Technology for Atherosclerosis Imaging
    Read more
  • SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Sepsis
    Read more
  • SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer
    Read more
  • SignaBlok Receives NCI Grant to Test New Approach to Lung Cancer Treatment
    Read more
  • SignaBlok Receives NIH Grant to Develop Targeted Imaging of Atherosclerosis
    Read more
  • SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
    Read more